跳转至内容
Merck
CN
  • Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.

Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.

The Journal of clinical investigation (2018-01-13)
Peter J Chockley, Jun Chen, Guoan Chen, David G Beer, Theodore J Standiford, Venkateshwar G Keshamouni
摘要

During epithelial-mesenchymal transition (EMT) epithelial cancer cells transdifferentiate into highly motile, invasive, mesenchymal-like cells, giving rise to disseminating tumor cells. Few of these disseminated cells successfully metastasize. Immune cells and inflammation in the tumor microenvironment were shown to drive EMT, but few studies investigated the consequences of EMT for tumor immunosurveillance. In addition to initiating metastasis, we demonstrate that EMT confers increased susceptibility to natural killer (NK) cells and contributes, in part, to the inefficiency of the metastatic process. Depletion of NK cells allowed spontaneous metastasis without affecting primary tumor growth. EMT-induced modulation of E-cadherin and cell adhesion molecule 1 (CADM1) mediated increased susceptibility to NK cytotoxicity. Higher CADM1 expression correlates with improved patient survival in 2 lung and 1 breast adenocarcinoma patient cohorts and decreased metastasis. Our observations reveal a novel NK-mediated, metastasis-specific immunosurveillance in lung cancer and present a window of opportunity for preventing metastasis by boosting NK cell activity.

材料
货号
品牌
产品描述

Sigma-Aldrich
抗小鼠IgG(全分子)-过氧化物酶 兔抗, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
单克隆抗 GAPDH-过氧物酶 小鼠抗, clone GAPDH-71.1, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
波形蛋白单克隆抗体 小鼠抗, clone VIM-13.2, ascites fluid
Sigma-Aldrich
抗-CADM1抗体, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Anti-SynCAM antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human CADM1